A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes

R Frederich, JH Alexander, FT Fiedorek… - Postgraduate …, 2010 - Taylor & Francis
Objective: The objective was to assess the relative risk (RR) for cardiovascular (CV) events
across all 8 randomized phase 2/3 trials evaluating saxagliptin in patients with type 2 …
被引用次数：285 相关文章

A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes.

R Frederich, JH Alexander, FT Fiedorek… - Postgraduate …, 2010 - europepmc.org
Objective The objective was to assess the relative risk (RR) for cardiovascular (CV) events
across all 8 randomized phase 2/3 trials evaluating saxagliptin in patients with type 2 …

A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes

R Frederich, JH Alexander… - Postgraduate …, 2010 - pubmed.ncbi.nlm.nih.gov
Objective The objective was to assess the relative risk (RR) for cardiovascular (CV) events
across all 8 randomized phase 2/3 trials evaluating saxagliptin in patients with type 2 …

[引用][C] A Systematic Assessment of Cardiovascular Outcomes in the Saxagliptin Drug Development Program for Type 2 Diabetes

R Frederich, JH Alexander, FT Fiedorek… - Postgraduate …, 2010 - cir.nii.ac.jp
A Systematic Assessment of Cardiovascular Outcomes in the Saxagliptin Drug Development
Program for Type 2 Diabetes | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ …